AMAG Pharmaceuticals, Inc. Expected to Post FY2019 Earnings of $0.68 Per Share (AMAG)

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Analysts at Leerink Swann issued their FY2019 EPS estimates for shares of AMAG Pharmaceuticals in a research note issued to investors on Tuesday. Leerink Swann analyst J. Schwartz anticipates that the specialty pharmaceutical company will post earnings per share of $0.68 for the year. Leerink Swann has a “Market Perform” rating and a $25.00 price target on the stock.

A number of other brokerages have also commented on AMAG. Cantor Fitzgerald set a $24.00 price target on shares of AMAG Pharmaceuticals and gave the stock a “hold” rating in a report on Monday, February 27th. Jefferies Group LLC set a $40.00 price target on shares of AMAG Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, March 18th. Zacks Investment Research lowered shares of AMAG Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, January 9th. Cowen and Company lowered shares of AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Friday, February 3rd. Finally, Raymond James Financial, Inc. reiterated an “underperform” rating on shares of AMAG Pharmaceuticals in a report on Monday, January 9th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $32.00.

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

ILLEGAL ACTIVITY NOTICE: This story was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://sportsperspectives.com/2017/04/21/amag-pharmaceuticals-inc-expected-to-post-fy2019-earnings-of-0-68-per-share-amag.html.

Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded up 0.333% on Friday, hitting $22.625. The stock had a trading volume of 416,878 shares. The firm’s market capitalization is $776.92 million. AMAG Pharmaceuticals has a 12-month low of $17.92 and a 12-month high of $36.83. The company has a 50 day moving average of $22.82 and a 200-day moving average of $26.53.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its earnings results on Tuesday, February 14th. The specialty pharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of $0.24 by $0.55. The business earned $151.60 million during the quarter, compared to analyst estimates of $155.12 million. AMAG Pharmaceuticals had a return on equity of 11.10% and a net margin of 3.12%. The firm’s revenue was up 39.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.12 earnings per share.

A number of institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC raised its position in AMAG Pharmaceuticals by 20.8% in the third quarter. Acadian Asset Management LLC now owns 4,520 shares of the specialty pharmaceutical company’s stock valued at $111,000 after buying an additional 777 shares during the last quarter. Nisa Investment Advisors LLC raised its position in AMAG Pharmaceuticals by 1,666.7% in the third quarter. Nisa Investment Advisors LLC now owns 5,300 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 5,000 shares during the last quarter. Sei Investments Co. raised its position in AMAG Pharmaceuticals by 93.3% in the third quarter. Sei Investments Co. now owns 8,287 shares of the specialty pharmaceutical company’s stock valued at $204,000 after buying an additional 4,000 shares during the last quarter. Seven Eight Capital LP purchased a new position in AMAG Pharmaceuticals during the fourth quarter valued at about $212,000. Finally, Gargoyle Investment Advisor L.L.C. purchased a new position in AMAG Pharmaceuticals during the third quarter valued at about $220,000.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

5 Day Chart for NASDAQ:AMAG

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply